Category: Side Effect: Cardiovascular (heart attack, stroke, heart failure, PE, DVT)
-
Danish Study Suggests Celebrex And Vioxx To Be Avoided After Heart Attack
Increased Risk Of Death For Post-Heart Attack Patients Taking COX-2 Drugs In mid-November 2005 it was reported that Merck’s Vioxx and Pfizer’s Celebrex, as well as some similar painkillers, increase the risk of death…
-
Merck Prevails In Its First New Jersey Vioxx Trial
Humeston Case Ends with Defense Verdict for Merck Merck & Co. got what it wanted in its first New Jersey Vioxx trial: a defense verdict. On November 3, 2005, a New Jersey state court…
-
Health Canada Put Adderall Back on the Market Based on “Inconclusive Evidence”
Safety of Adderall Cannot be Adequately Evaluated Says Expert Committee Chairman In the October 11, 2005 edition of the Canadian Medical Association Journal ("CMAJ"), an article by Wayne Kondro reveals that Health Canada reintroduced…
-
Cardiac Drug ReoPro: Clinical Trial Is Suspended by Lilly and J&J
Drug Companies Had Been Testing ReoPro for Treatment of Ischemic Strokes On October 5, 2005 it was reported that Eli Lilly & Co. ("Lilly") and Johnson & Johnson ("J&J") have temporarily suspended a late-stage…
-
Pfizer Agrees to New Celebrex Safety Guidelines in Canada
Health Canada Revisions to Celebrex Label Accepted by Pfizer Canada On September 21, 2005 Pfizer Canada announced the drug company had agreed to make changes suggested by Health Canada that add new safety guidelines…
-
Even One Day of Vioxx Use Can Cause Heart Attack or Stroke Says Expert
Dr. Benedict Lucchesi Testifies at Humeston Vioxx Trial in New Jersey Dr. Benedict Lucchesi, a prominent heart and medication expert from the University of Michigan, told the jury hearing evidence at the Humeston Vioxx…
-
Anti-Cancer Drug Herceptin Associated With Significant Risk of Cardiotoxicity
Genentech Says Its Breast Cancer Drug Can Increase Risk of Heart Problems The FDA and Genentech, Inc. have warned healthcare professionals by means of an August 2005 "Dear Doctor" letter of study data linking…
-
Adderall: Health Canada Allows Shire’s ADHD Drug Back on Market
Sudden Cardiac Death and Stroke Case Reports Had Caused Health Canada to Recall Adderall in February 2005 Health Canada announced on August 24, 2005 that Adderall XR, an attention deficit hyperactivity disorder ("ADHD") drug,…
-
Abbott’s Weight-loss Drug Meridia Gets a Confidence Vote by FDA
FDA Denies Public Citizen’s Petition to Remove Meridia from Market The FDA has decided that the benefits of Abbott Laboratories’ prescription weight-loss drug Meridia continue to outweigh the drug’s risks for select obese…
-
Health Canada Not in Any Rush to Return Vioxx to Pharmacies
Expert Panel Finds That Vioxx is Safe Enough — But is it, Really? Health Canada is balking, so to speak, at the recommendation of an expert panel it appointed to consider the issue of…